Table 4 Subgroup analysis of disease progression rate
Uncorrected disease progression rate, points/year, mean (95% CI) | Covariate-corrected disease progression rate, points/year, mean (95% CI) | Maximum extent of placebo effect, points mean (95% CI) | |
|---|---|---|---|
Overall | 5.77 (5.60, 5.94) | 5.86 (5.75, 5.97) | − 1.89 (− 2.08, − 1.69) |
Publication year | |||
< 2008 | 6.13 (5.89, 6.39) | 5.92 (5.80, 6.04) | − 1.70 (− 2.04, − 1.36) |
≥ 2008 | 5.56 (5.40, 5.73) | 5.81 (5.72, 5.92) | − 2.03 (− 2.24, − 1.81) |
Trial design | |||
Add-on | 5.53 (5.26, 5.80) | 5.85 (5.69, 6.00) | − 1.92 (− 2.25, − 1.59) |
Non-add-on | 5.84 (5.64, 6.04) | 5.87 (5.74, 6.01) | − 1.88 (− 2.11, − 1.65) |
Regions | |||
International | 5.81 (5.66, 5.97) | 5.78 (5.67, 5.90) | − 2.17 (− 2.39, − 1.95) |
North America | 5.62 (5.35, 5.89) | 6.11 (6.00, 6.23) | − 1.50 (− 1.69, − 1.31) |
Europe/Oceania | 5.58 (4.68, 6.48) | 5.54 (4.79, 6.29) | − 2.35 (− 3.80, − 0.90) |
East Asia | 5.67 (5.15, 6.19) | 5.45 (4.93, 5.97) | − 2.43 (− 3.45, − 1.41) |
Middle Asia | 7.00 (5.98, 8.02) | 6.76 (6.20, 7.31) | − 0.01 (− 1.31, 1.28) |
South America | 7.27 (6.49, 8.06) | 6.27 (5.48, 7.06) | − 1.35 (− 2.11, − 0.60) |